Good morning, everyone, and how are you today? We are doing just fine, thank you, despite persistently soggy and gloomy skies hovering over the Pharmalot campus. As the Morning Mayor used to say: “Every brand new day should be unwrapped like a precious gift.” So while you tug on the ribbon and ponder the possibilities, we will brew another cup of stimulation and proceed with our usual routine of foraging for interesting items. Speaking of which, here are a few tidbits to get you going. Have a smashing day and do keep in touch. …
A coalition of pharmaceutical industry critics is accusing the largest drug makers of hiding behind research and development “as an excuse for price-gouging American patients,” STAT writes. And they cite a new study that finds drug makers spent about 22% of their revenues on research and development in 2017 to prove their point. The study, commissioned by the Campaign for Sustainable Rx Pricing, was based largely on analysis of 2017 Security and Exchange Commission filings for the 10 largest U.S.-based drug makers that generate more than half their revenue from medicines.
About the Author Reprints
One wonders how much of the 340B increase is due to the increase in the base cost of the purchased product? That is an area that the article does not address, while it does seem to make a case that the absolute growth as opposed to the manufacturers net should be troubling.